Cell type expression pattern of predictive gene signatures
CEL files from sorted cell type samples from IRIS (GSE22886 [5] ) and the Human body index (GSE7307) were normalized separately using frma [6] . In GSE7307, we extracted the profiles from all immune cells (32 profiles from monocyte, T cell and B cell lineages) and colon tissues (2 profiles). We created a combined cell type gene expression matrix, corrected for dataset of origin effects using Combat [7] , and subsequently averaged probesets into genes. This resulted in the creation of an expression matrix of 130 expression profiles (Supplementary Table S2 ), which we then standardized using zscores and averaged into major cell lineages split into resting and activation/memory state.
The assign signature genes to the most likely contributing cell subpopulations they were detected from in the samples, we assigned each gene to the three most expressing cell subsets, and counted how many unique genes were assigned to each of 8 major functional cell lineages (Supplementary Table S3 ). Since we looked for enrichment of cell type expression, we restricted the analysis to the 122 signatures genes up-regulated in non-responders, of which 109 genes could be mapped to probesets in the sorted cell compendium data.
IBD cohorts' gene expression data
The gene expression data for each IBD cohort used in the deconvolution meta-analysis were obtained from 3 GEO datasets [8] : UC-A from GSE14580, UC-B form GSE12251
and CDc from GSE16879. These datasets contain biopsy gene expression profiles generated from 2 cohorts of UC patients (Cohort A and B in GSE14580 and GSE12251 respectively), and 1 cohort of CD patients (part of GSE16879). They were originally designed for the discovery of gene signatures that can predict, at baseline, if a patient is likely to respond to an anti-TNFα treatment (Infliximab) [1, 3] . In terms of signatures, all signatures were identified from baseline gene expression differential analysis between responders and non-responders to Infliximab treatment in the same set of 3 IBD cohorts of UC (cohorts UC-A and UC-B) or CD (cohort CDc) patients [1, 3] , exception being the IRRAT signature which, subsequent to the study it originated with, was found to correlate with anti-TNFα response at baseline in the UC-B cohort [9] . In addition, we obtained blood gene expression data of IBD patients for whom endoscopic activity was available (GSEXXX) [REF] , in which we assessed the relation of the CCL7-CCR2-TREM1 axis to monitor disease activity.
Signature scores and ROC analysis
ROC analyses were performed on signature expression scores that summarize, for each sample, the expression level of all the genes in a predictive gene set [10] . Given a gene expression dataset (including data adjusted for proportion variations) and a gene signature/set, the signature score S j for sample j was computed as:
where g i is the expression level of the i-th gene of the signature in sample j, and d i is the sign of the difference between its mean expression in nonresponders and responders.
For adjusted data where negative expression values occurred, we shifted the data by = -+1, where is the minimum expression value amongst the signature genes.
ROC curve analysis of cellular biomarkers were computed either directly on estimated proportions for individual cell subsets. AUC values were computed using the R package pROC.
To assess whether the observed drops in AUC could result from the reduction in degrees of freedom incurred by the adjustment procedure itself, we repeatedly adjusted the data with random pairs of cell subset proportions and compared the derived "random" AUCs with the ones obtained using actual estimated proportions (Supplementary Figure S7B) . This showed that all observed AUC differences were statistically significant (all p-values≤0.018). We also visualized the adjusted gene expression datasets ordered according to their respective signature score data, which confirmed that the association between signature scores and treatment response status was lost after adjustment
Response classification by a decision algorithm
In patients with CD, clinical remission was defined as cessation of diarrhea and abdominal cramping or, in the cases of patients with fistulas, cessation of fistula drainage and complete closure of all draining fistulas at week 14, coupled with a decision of the treating physician to continue IFX therapy at the current dosing and schedule. Partial response was defined as a reduction in the amount of diarrhea and abdominal cramping, or, in the case of fistula patients, a decrease in the drainage, size, or number of fistulas at last follow-up. In patients with UC, clinical remission was defined as cessation of diarrhea, rectal bleeding, and abdominal cramping at week 14 as indicated in the patient's chart by the treating physician, coupled with a decision of the treating physician to continue IFX therapy at the current dosing and schedule, whereas partial response was defined as a reduction in the amount of diarrhea, rectal bleeding, and abdominal cramping. Outcomes not meeting one of the above definitions were classified as non-response.
To further stratify the response, patients deemed as partial responders was allocated to a decision tree following these steps: failure to withdraw steroid treatment at week 14 was deemed as therapeutic failure. In patients not treated with steroids, a substantial decrease (>50%) in biomarker dynamics (fecal calprotectin if available and serum CRP when calprotectin was not available), as an indicator of response to treatment. For subjects who were not steroid dependent and exhibited no substantial biomarker dynamics, response was defined according to the clinical state at week 26.
IFX levels and antibodies to IFX (ATI) measurements [11, 12] were available for 28 of the patients. From these, we excluded responders for which 2 subsequent IFX level measurements below 3 (µg/ml) were observed prior to week 26, assuming their response status was unlikely to be IFX related, and non-responders with measurements of ATI level above 15 (µg/mL), assuming they had a secondary loss of response, unrelated TNFα blockade.
In total, applying this decision tree criteria left 29 responders and 23 non-responders from the two centers.
Immuno-histochemistry markers
We examined plasma cell frequencies by CD138+ IHC staining. For inflammatory macrophages, our in-silico deconvolution analysis relied on a gene expression signature of monocyte derived macrophages bearing typical macrophage morophology and phagocytic activity [5] . Given the disease context, this suggested a bias towards inflammatory macrophage phenotype (M1), as such, the expert pathologist performing the IHC, assessed the co-expression of the CD68 and CD86 as well as cell morphology, as these markers are co-expressed by monocytes and CD86 also in other cell subsets Figure 2 . For each signature, we provide its member genes and their respective annotations. 
Table S5. Estimated immune cell subset proportions
Estimated proportions in all cohorts at baseline and after treatment. 
